These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25271212)

  • 1. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
    Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
    J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.
    He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Li CF
    Histopathology; 2015 Jun; 66(7):991-1002. PubMed ID: 25393083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.
    Chen TJ; He HL; Shiue YL; Yang CC; Lin LC; Tian YF; Chen SH
    Int J Med Sci; 2018; 15(11):1171-1178. PubMed ID: 30123054
    [No Abstract]   [Full Text] [Related]  

  • 6. Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
    Lee YY; Li CF; Lin CY; Lee SW; Sheu MJ; Lin LC; Chen TJ; Wu TF; Hsing CH
    Tumour Biol; 2014 Nov; 35(11):11097-105. PubMed ID: 25099619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients?
    Jung KU; Kim HC; Park JO; Park YS; Park HC; Choi DH; Cho YB; Yun SH; Lee WY; Chun HK
    J Surg Oncol; 2015 Mar; 111(4):439-44. PubMed ID: 25488390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
    He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Hsing CH; Huang HY; Wang JY; Li CF
    J Surg Oncol; 2014 Dec; 110(8):1002-10. PubMed ID: 25155043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance.
    Lin CY; Sheu MJ; Li CF; Lee SW; Lin LC; Wang YF; Chen SH
    Tumour Biol; 2014 Jul; 35(7):6823-30. PubMed ID: 24729124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.
    Sheu MJ; Li CF; Lin CY; Lee SW; Lin LC; Chen TJ; Ma LJ
    Tumour Biol; 2014 Aug; 35(8):7755-63. PubMed ID: 24810927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
    Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
    Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
    Edden Y; Wexner SD; Berho M
    Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
    Lee YE; He HL; Shiue YL; Lee SW; Lin LC; Wu TF; Chang IW; Lee HH; Li CF
    Tumour Biol; 2015 Sep; 36(10):7675-83. PubMed ID: 25929810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
    Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
    Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of DSG3 in rectal adenocarcinoma treated with preoperative chemoradiotherapy.
    Chao TB; Li CF; Lin CY; Tian YF; Chang IW; Sheu MJ; Lee YE; Chan TC; He HL
    Future Oncol; 2016 Jun; 12(12):1457-67. PubMed ID: 27040321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
    Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
    Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    He HL; Lee YE; Chen HP; Hsing CH; Chang IW; Shiue YL; Lee SW; Hsu CT; Lin LC; Wu TF; Li CF
    Exp Mol Pathol; 2015 Jun; 98(3):338-45. PubMed ID: 25805104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.